Sutureless aspiration cutter biopsy is beneficial in diagnosing ocular cancers

Article

Sutureless aspiration cutter biopsy can be used to diagnose ocular cancers such as orbital lymphoma.

Sutureless aspiration cutter biopsy can be used to diagnose ocular cancers such as orbital lymphoma, according to a paper featured in the European Journal of Ophthalmology.

Dr Paul T. Finger et al., New York Eye Cancer Center, New York, USA, included three patients in the study with orbital adnexal tumours. Each participant underwent orbital biopsy via a 3 mm incision into the eyelid or conjunctival fornix.

A bimanual technique was used to introduce standard aspiration cutters into the anterior and posterior orbital tumours. The team conducted cytopathology, histopathology and immunohistochemical analysis on all three patients.

The diagnoses were orbital lymphoma, metastatic endometrial adenocarcinoma, and metastatic prostate cancer, with the 20G aspiration cutter yielding the most tissue. The small incisions did not require any sutures.

The technique was strongly linked to fine needle aspiration biopsy, controlled aspiration and enclosed mechanical cutting.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.